Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells
Sibylle Madlener(Comprehensive Cancer Center Vienna), Thomas Szekeres(Medical University of Vienna), Georg Krupitza(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Grusch(Comprehensive Cancer Center Vienna), Astrid Bernhaus(Vienna General Hospital), Irene Herbacek(Comprehensive Cancer Center Vienna), Annemarie Losert(Medical University of Vienna), Philipp Saiko(Ludwig Boltzmann Institute Applied Diagnostics), Monika Fritzer‐Szekeres(Vienna General Hospital), Howard L. Elford(Molecules for Health (United States)), Christoph Illmer(Vienna General Hospital)
Cited by 143
Related Papers
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
|PLoS ONE|2011|437
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
|Annals of Oncology|2013|403
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
|Nature Medicine|2022|395
Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure–activity relationship
|Biochemical Pharmacology|2005|303